The success of HBED and its bifunctional counterpart(N,N′-bis-[2-hydroxy-5-(carboxyethyl)­benzyl]­ethylenediamine-N,N′-diacetic acid, HBED-CC) haveculminated in 2020 in the FDA approval of [68Ga]­Ga-HBED-CC-PSMA(i.e., PSMA-11) for the imaging of prostate tumors.−, The gene discussed is FOLH1; the disease is prostate neoplasm.